AstraZeneca: to assume sole responsibility for gut drug

(CercleFinance.com) - AstraZeneca will take sole responsibility for developing, manufacturing and commercialising intestinal drug Linzess in China, the company said on Wednesday.


The drugmaker said it has amended its collaboration agreement with Ironwood in China, Hong Kong and Macau for this new treatment of patients with irritable bowel syndrome with constipation.

As part of the deal, AstraZeneca will make Ironwood three payments, totalling 35 million dollars between 2021 and 2024.

In addition, Ironwood could receive up to 90 million dollars in milestone payments, as well as royalties from sales.

There are approximately 14 million adults suffering from irritable bowel syndrome with constipation in China alone.

Copyright (c) 2019 CercleFinance.com. All rights reserved.